Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...
It has been about a month since the last earnings report for Repligen (RGEN). Shares have added about 21.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...
Hosted on MSN
Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results , with sales up 14.8% year on year to $182.4 million. The company’s full-year revenue guidance of $725 ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% ...
A month has gone by since the last earnings report for Repligen (RGEN). Shares have lost about 11.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...
Repligen (NASDAQ:RGEN) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...
We recently published Top 10 Stock Recommendations You Can’t Miss Amid Growing AI Bubble Fears. Repligen Corporation (NASDAQ:RGEN) is one of the top recommended stocks. Dan Veru, Palisade Capital ...
Long-term shareholders of bioprocessing kingpinRepligen Corporation watched with glee as their shares increased about 1,000% over the five-year period ending last summer.Then the stock came crashing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback